Press Releases

Addition of Clinical Sites Ahead of Projections Bethesda, Maryland, May 25, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax®... Read More

Talk will highlight early clinical data, and the phase II clinical trial design Bethesda, Maryland, May 20, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chief Technical Officer, Dr. Marnix Bosch, will give a presentation on “Autologous Dendritic Cells for Glioblastoma” on Saturday, on May 21, at 1:45 pm at the 14thAnnual Meeting of the American Society of Cell and Gene Therapy in Seattle, WA. Dr.... Read More

Bethesda, Maryland, May 18, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe. Fraunhofer is the largest applied research foundation in Europe, with a staff of more than 18,000 scientists, engineers, business personnel and others dedicated to practical applications and... Read More

Number Of Centers Further Expected To More Than Double This Quarter Bethesda, Maryland, May 3, 2011 — Northwest Biotherapeutics (OTC.BB:NWBO) today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the... Read More

Bethesda, Maryland, March 16, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO). Taking note of the recent unusual activity in the Company’s stock, Northwest Biotherapeutics (NWBT) commented today that it is not aware of any basis relating to the Company or its products or programs. The Company is continuing to move forward with the trial-related activities for its large, 240-patient clinical trial for GBM brain cancer. The... Read More